Zolunicant hydrochloride is a Small Molecule owned by Mind Medicine MindMed, and is involved in 5 clinical trials, of which 3 were completed, and 2 are planned.

18-Methoxycoronaridine (18-MC) modulates dopamine fluctuations in the mesolimbic system of the brain. It targets the dopamine reward pathway involved in all forms of addictive disorders. It is a non-competitive negative allosteric modulator that acts by stabilizing the ligand bound, desensitized state of the receptor. It binds with higher affinity to the desensitized than to the resting state of the alpha-3-beta-4 nicotinic receptor, and induces the desensitization process.

The revenue for Zolunicant hydrochloride is expected to reach a total of $493m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Zolunicant hydrochloride NPV Report.

Zolunicant hydrochloride was originated by University of Vermont and Albany Medical College and is currently owned by Mind Medicine MindMed.

Zolunicant hydrochloride Overview

18-Methoxycoronaridine (18-MC) is under development for the treatment of leishmaniasis, substance addictions including cocaine, opiate, methamphetamine, nicotine, alcohol and opioid use disorders. The drug candidate is administered orally. The drug candidate is an alpha-3-beta-4 nicotinic receptor antagonist. It is a new chemical entity.

It was also under development for the treatment of obesity, other forms of compulsive behavior. It is a psychedelic drug.

Mind Medicine MindMed Overview

Mind Medicine MindMed (MindMed) is a neuro-pharmaceutical company. It develops, discovers and deploys psychedelic inspired medicines to promote wellness, improve health, and alleviate suffering. MindMed is headquartered in New York, the US.

The operating loss of the company was US$93.9 million in FY2021, compared to an operating loss of US$33 million in FY2020. The net loss of the company was US$93 million in FY2021, compared to a net loss of US$33.9 million in FY2020.

Quick View – Zolunicant hydrochloride

Report Segments
  • Innovator
Drug Name
  • Zolunicant hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Infectious Disease
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.